Which has better earnings & valuation, ESTA or INMD?

InMode has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Establishment Labs $245.82M 9.27 -$51.06M -$1.31 N/A InMode $370.49M 2.38 $93.83M $1.23 12.45

Is ESTA or INMD more profitable?

InMode has a net margin of 20.69% compared to Establishment Labs' net margin of -15.82%. InMode's return on equity of 11.99% beat Establishment Labs' return on equity. Company Net Margins Return on Equity Return on Assets Establishment Labs -15.82% -205.79% -10.75% InMode 20.69% 11.99% 10.60%

Does the media prefer ESTA or INMD?

In the previous week, Establishment Labs had 14 more articles in the media than InMode. MarketBeat recorded 18 mentions for Establishment Labs and 4 mentions for InMode. InMode's average media sentiment score of 1.18 beat Establishment Labs' score of 0.18 indicating that InMode is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 3 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral InMode 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, TMDX or INMD?

TransMedics Group has higher revenue and earnings than InMode. InMode is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransMedics Group $668.47M 4.34 $190.29M $3.89 21.57 InMode $370.49M 2.38 $93.83M $1.23 12.45

Does the media favor TMDX or INMD?

In the previous week, TransMedics Group had 26 more articles in the media than InMode. MarketBeat recorded 30 mentions for TransMedics Group and 4 mentions for InMode. InMode's average media sentiment score of 1.18 beat TransMedics Group's score of 0.03 indicating that InMode is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 6 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral InMode 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, PLSE or INMD?

InMode has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulse Biosciences $350K 8,386.27 -$72.78M -$1.18 N/A InMode $370.49M 2.38 $93.83M $1.23 12.45

Is PLSE or INMD more profitable?

InMode has a net margin of 20.69% compared to Pulse Biosciences' net margin of -6,755.78%. InMode's return on equity of 11.99% beat Pulse Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Pulse Biosciences -6,755.78% -100.22% -84.29% InMode 20.69% 11.99% 10.60%

Does the media favor PLSE or INMD?

In the previous week, Pulse Biosciences had 5 more articles in the media than InMode. MarketBeat recorded 9 mentions for Pulse Biosciences and 4 mentions for InMode. InMode's average media sentiment score of 1.18 beat Pulse Biosciences' score of -0.55 indicating that InMode is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Negative InMode 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, INMD or LMAT?

InMode has higher revenue and earnings than LeMaitre Vascular. InMode is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InMode $370.49M 2.38 $93.83M $1.23 12.45 LeMaitre Vascular $249.60M 7.46 $57.73M $2.85 28.58

Is INMD or LMAT more profitable?

LeMaitre Vascular has a net margin of 25.02% compared to InMode's net margin of 20.69%. LeMaitre Vascular's return on equity of 15.63% beat InMode's return on equity. Company Net Margins Return on Equity Return on Assets InMode 20.69% 11.99% 10.60% LeMaitre Vascular 25.02% 15.63% 10.06%

Does the media prefer INMD or LMAT?

In the previous week, LeMaitre Vascular had 28 more articles in the media than InMode. MarketBeat recorded 32 mentions for LeMaitre Vascular and 4 mentions for InMode. InMode's average media sentiment score of 1.18 beat LeMaitre Vascular's score of -0.04 indicating that InMode is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMode 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LeMaitre Vascular 3 Very Positive mention(s) 6 Positive mention(s) 10 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, INMD or AXGN?

InMode has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InMode $370.49M 2.38 $93.83M $1.23 12.45 AxoGen $225.21M 11.08 -$15.70M -$0.68 N/A

Is INMD or AXGN more profitable?

InMode has a net margin of 20.69% compared to AxoGen's net margin of -13.36%. InMode's return on equity of 11.99% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets InMode 20.69% 11.99% 10.60% AxoGen -13.36% -8.90% -6.47%

Does the media favor INMD or AXGN?

In the previous week, AxoGen had 15 more articles in the media than InMode. MarketBeat recorded 19 mentions for AxoGen and 4 mentions for InMode. InMode's average media sentiment score of 1.18 beat AxoGen's score of 0.07 indicating that InMode is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMode 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AxoGen 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

InMode (INMD) Competitors

$15.31 +0.19 (+1.26%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$15.10 -0.21 (-1.38%)

As of 08/7/2026 07:34 PM Eastern

Compare

INMD vs. ESTA, TMDX, PLSE, LMAT, and AXGN

Should you buy InMode stock or one of its competitors? MarketBeat compares InMode with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with InMode include Establishment Labs (ESTA), TransMedics Group (TMDX), Pulse Biosciences (PLSE), LeMaitre Vascular (LMAT), and AxoGen (AXGN). These companies are all part of the "healthcare equipment" industry.

How does InMode compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and InMode (NASDAQ:INMD) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

InMode has a net margin of 20.69% compared to Establishment Labs' net margin of -15.82%. InMode's return on equity of 11.99% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-15.82%	-205.79%	-10.75%
InMode	20.69%	11.99%	10.60%

72.9% of Establishment Labs shares are held by institutional investors. Comparatively, 68.0% of InMode shares are held by institutional investors. 10.0% of Establishment Labs shares are held by insiders. Comparatively, 6.9% of InMode shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Establishment Labs currently has a consensus price target of $100.25, suggesting a potential upside of 29.49%. InMode has a consensus price target of $16.00, suggesting a potential upside of 4.51%. Given Establishment Labs' stronger consensus rating and higher possible upside, equities research analysts clearly believe Establishment Labs is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Establishment Labs had 14 more articles in the media than InMode. MarketBeat recorded 18 mentions for Establishment Labs and 4 mentions for InMode. InMode's average media sentiment score of 1.18 beat Establishment Labs' score of 0.18 indicating that InMode is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	3 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
InMode	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Establishment Labs has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market. Comparatively, InMode has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market.

InMode has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$245.82M	9.27	-$51.06M	-$1.31	N/A
InMode	$370.49M	2.38	$93.83M	$1.23	12.45

Summary

InMode beats Establishment Labs on 9 of the 16 factors compared between the two stocks.

How does InMode compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and InMode (NASDAQ:INMD) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

TransMedics Group has a net margin of 22.69% compared to InMode's net margin of 20.69%. TransMedics Group's return on equity of 15.88% beat InMode's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	22.69%	15.88%	5.95%
InMode	20.69%	11.99%	10.60%

TransMedics Group presently has a consensus price target of $124.18, indicating a potential upside of 48.03%. InMode has a consensus price target of $16.00, indicating a potential upside of 4.51%. Given TransMedics Group's stronger consensus rating and higher possible upside, analysts clearly believe TransMedics Group is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, TransMedics Group had 26 more articles in the media than InMode. MarketBeat recorded 30 mentions for TransMedics Group and 4 mentions for InMode. InMode's average media sentiment score of 1.18 beat TransMedics Group's score of 0.03 indicating that InMode is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	6 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
InMode	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.7% of TransMedics Group shares are held by institutional investors. Comparatively, 68.0% of InMode shares are held by institutional investors. 6.9% of TransMedics Group shares are held by insiders. Comparatively, 6.9% of InMode shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

TransMedics Group has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market. Comparatively, InMode has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market.

TransMedics Group has higher revenue and earnings than InMode. InMode is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$668.47M	4.34	$190.29M	$3.89	21.57
InMode	$370.49M	2.38	$93.83M	$1.23	12.45

Summary

TransMedics Group beats InMode on 13 of the 16 factors compared between the two stocks.

How does InMode compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and InMode (NASDAQ:INMD) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

In the previous week, Pulse Biosciences had 5 more articles in the media than InMode. MarketBeat recorded 9 mentions for Pulse Biosciences and 4 mentions for InMode. InMode's average media sentiment score of 1.18 beat Pulse Biosciences' score of -0.55 indicating that InMode is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Negative
InMode	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pulse Biosciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market. Comparatively, InMode has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market.

Pulse Biosciences currently has a consensus target price of $32.33, indicating a potential downside of 23.76%. InMode has a consensus target price of $16.00, indicating a potential upside of 4.51%. Given InMode's higher probable upside, analysts plainly believe InMode is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 68.0% of InMode shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by company insiders. Comparatively, 6.9% of InMode shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

InMode has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	8,386.27	-$72.78M	-$1.18	N/A
InMode	$370.49M	2.38	$93.83M	$1.23	12.45

InMode has a net margin of 20.69% compared to Pulse Biosciences' net margin of -6,755.78%. InMode's return on equity of 11.99% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	-6,755.78%	-100.22%	-84.29%
InMode	20.69%	11.99%	10.60%

Summary

InMode beats Pulse Biosciences on 10 of the 16 factors compared between the two stocks.

How does InMode compare to LeMaitre Vascular?

InMode (NASDAQ:INMD) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

In the previous week, LeMaitre Vascular had 28 more articles in the media than InMode. MarketBeat recorded 32 mentions for LeMaitre Vascular and 4 mentions for InMode. InMode's average media sentiment score of 1.18 beat LeMaitre Vascular's score of -0.04 indicating that InMode is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMode	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LeMaitre Vascular	3 Very Positive mention(s)	6 Positive mention(s)	10 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral

68.0% of InMode shares are held by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are held by institutional investors. 6.9% of InMode shares are held by company insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

InMode has a beta of 1.89, suggesting that its share price is 89% more volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

InMode currently has a consensus price target of $16.00, suggesting a potential upside of 4.51%. LeMaitre Vascular has a consensus price target of $110.60, suggesting a potential upside of 35.79%. Given LeMaitre Vascular's stronger consensus rating and higher probable upside, analysts clearly believe LeMaitre Vascular is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LeMaitre Vascular	0 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.44

InMode has higher revenue and earnings than LeMaitre Vascular. InMode is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMode	$370.49M	2.38	$93.83M	$1.23	12.45
LeMaitre Vascular	$249.60M	7.46	$57.73M	$2.85	28.58

LeMaitre Vascular has a net margin of 25.02% compared to InMode's net margin of 20.69%. LeMaitre Vascular's return on equity of 15.63% beat InMode's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMode	20.69%	11.99%	10.60%
LeMaitre Vascular	25.02%	15.63%	10.06%

Summary

LeMaitre Vascular beats InMode on 11 of the 16 factors compared between the two stocks.

How does InMode compare to AxoGen?

InMode (NASDAQ:INMD) and AxoGen (NASDAQ:AXGN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

InMode currently has a consensus target price of $16.00, indicating a potential upside of 4.51%. AxoGen has a consensus target price of $51.00, indicating a potential upside of 9.84%. Given AxoGen's stronger consensus rating and higher possible upside, analysts clearly believe AxoGen is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

InMode has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market. Comparatively, AxoGen has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

InMode has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMode	$370.49M	2.38	$93.83M	$1.23	12.45
AxoGen	$225.21M	11.08	-$15.70M	-$0.68	N/A

InMode has a net margin of 20.69% compared to AxoGen's net margin of -13.36%. InMode's return on equity of 11.99% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMode	20.69%	11.99%	10.60%
AxoGen	-13.36%	-8.90%	-6.47%

68.0% of InMode shares are owned by institutional investors. Comparatively, 80.3% of AxoGen shares are owned by institutional investors. 6.9% of InMode shares are owned by company insiders. Comparatively, 2.4% of AxoGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, AxoGen had 15 more articles in the media than InMode. MarketBeat recorded 19 mentions for AxoGen and 4 mentions for InMode. InMode's average media sentiment score of 1.18 beat AxoGen's score of 0.07 indicating that InMode is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMode	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AxoGen	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

InMode beats AxoGen on 10 of the 16 factors compared between the two stocks.

Get InMode News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INMD vs. The Competition

Export

Metric	InMode	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$880.03M	$5.82B	$7.02B	$13.00B
Dividend Yield	N/A	1.78%	2.58%	10.20%
P/E Ratio	12.45	24.26	271.11	25.19
Price / Sales	2.38	62.05	590.37	78.11
Price / Cash	10.26	33.10	71.81	50.72
Price / Book	1.40	5.70	13.25	6.22
Net Income	$93.83M	$148.58M	$3.45B	$342.66M
7 Day Performance	1.12%	4.75%	4.67%	4.41%
1 Month Performance	2.00%	0.71%	-1.28%	-1.10%
1 Year Performance	8.50%	4.93%	77.33%	23.99%

InMode Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INMD InMode	1.346 of 5 stars	$15.31 +1.3%	$16.00 +4.5%	+8.5%	$880.03M	$370.49M	12.45	480	Positive News Earnings Report Analyst Forecast
ESTA Establishment Labs	3.2882 of 5 stars	$92.80 +0.3%	$93.75 +1.0%	+122.5%	$2.72B	$211.08M	N/A	1,004	Trending News Earnings Report Analyst Forecast Gap Up
TMDX TransMedics Group	4.4264 of 5 stars	$81.55 +6.6%	$126.27 +54.8%	-26.7%	$2.64B	$605.49M	18.53	210	Earnings Report Analyst Forecast
PLSE Pulse Biosciences	1.2887 of 5 stars	$37.73 +7.4%	$32.33 -14.3%	+188.3%	$2.43B	$350K	N/A	140	News Coverage Earnings Report Analyst Downgrade
LMAT LeMaitre Vascular	4.5429 of 5 stars	$103.61 +2.3%	$112.60 +8.7%	-11.7%	$2.32B	$256.28M	38.23	490	Trending News Earnings Report Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INMD) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InMode (INMD) Competitors

INMD vs. ESTA, TMDX, PLSE, LMAT, and AXGN

How does InMode compare to Establishment Labs?

Summary

How does InMode compare to TransMedics Group?

Summary

How does InMode compare to Pulse Biosciences?

Summary

How does InMode compare to LeMaitre Vascular?

Summary

How does InMode compare to AxoGen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMD vs. The Competition

InMode Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InMode (INMD) Competitors

INMD vs. ESTA, TMDX, PLSE, LMAT, and AXGN

How does InMode compare to Establishment Labs?

Is ESTA or INMD more profitable?

Do insiders and institutionals have more ownership in ESTA or INMD?

Do analysts recommend ESTA or INMD?

Does the media prefer ESTA or INMD?

Which has more risk and volatility, ESTA or INMD?

Which has better earnings & valuation, ESTA or INMD?

Summary

How does InMode compare to TransMedics Group?

Is TMDX or INMD more profitable?

Do analysts rate TMDX or INMD?

Does the media favor TMDX or INMD?

Do insiders & institutionals believe in TMDX or INMD?

Which has more risk and volatility, TMDX or INMD?

Which has preferable earnings and valuation, TMDX or INMD?

Summary

How does InMode compare to Pulse Biosciences?

Does the media favor PLSE or INMD?

Which has more volatility & risk, PLSE or INMD?

Do analysts recommend PLSE or INMD?

Do insiders and institutionals believe in PLSE or INMD?

Which has preferable earnings & valuation, PLSE or INMD?

Is PLSE or INMD more profitable?

Summary

How does InMode compare to LeMaitre Vascular?

Does the media prefer INMD or LMAT?

Do insiders & institutionals hold more shares of INMD or LMAT?

Which has more volatility and risk, INMD or LMAT?

Do analysts prefer INMD or LMAT?

Which has preferable valuation & earnings, INMD or LMAT?

Is INMD or LMAT more profitable?

Summary

How does InMode compare to AxoGen?

Do analysts prefer INMD or AXGN?

Which has more risk & volatility, INMD or AXGN?

Which has higher valuation and earnings, INMD or AXGN?

Is INMD or AXGN more profitable?

Do institutionals and insiders believe in INMD or AXGN?

Does the media favor INMD or AXGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMD vs. The Competition

InMode Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools